Zhejiang AngLiKang Pharmaceutical CO.,LTD. (SHE:002940)
China flag China · Delayed Price · Currency is CNY
24.36
-0.84 (-3.33%)
Sep 10, 2026, 1:15 PM CST

SHE:002940 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
1,3061,4031,5131,6211,5601,375
Other Revenue
21.5521.5524.78-8.095.48
1,3271,4251,5381,6211,5681,380
Revenue Growth
-6.17%-7.35%-5.10%3.32%13.62%7.03%
Cost of Revenue
806.46867.21925.32913.72674.86488.02
Gross Profit
521.02557.6612.57706.85893.58892.36
Selling, General & Admin
245.1251.37274.01396.04631.65671.11
Research & Development
124.98144.05214.34143.37112.6252.55
Other Operating Expenses
13.1711.536.135.338.5614.8
Operating Expenses
381.7405.41494.2543.21751.81741.11
Operating Income
139.33152.19118.37163.64141.77151.25
Interest Expense
-13-13-16.6-14.17-6.39-0.37
Interest & Investment Income
13.6713.6718.9621.9517.5225.78
Currency Exchange Gain (Loss)
0.310.317.212.441.27-0.58
Other Non Operating Income (Expenses)
-7.96-0.61-0.43-0.72-1.69-0.36
EBT Excluding Unusual Items
132.34152.56127.51173.13152.48175.72
Gain (Loss) on Sale of Investments
-20.88-17.68-5.69-1.7-2.96-9.05
Gain (Loss) on Sale of Assets
0.03-0.03-0.01-0.04-0.39-0.59
Asset Writedown
0.45-1.34-2.93-1.96-2.18-
Other Unusual Items
46.7746.7739.4937.77-6.56
Pretax Income
158.7180.28158.37207.2146.94172.65
Income Tax Expense
18.1923.546.4824.1314.9631.32
Earnings From Continuing Operations
140.51156.73151.89183.06131.99141.32
Minority Interest in Earnings
-26.06-31.29-71.56-44.69-4.69-21.48
Net Income
114.44125.4480.33138.37127.3119.84
Net Income to Common
114.44125.4480.33138.37127.3119.84
Net Income Growth
46.42%56.15%-41.94%8.70%6.22%-26.80%
Shares Outstanding (Basic)
204202201201199200
Shares Outstanding (Diluted)
204202201201199200
Shares Change
1.78%0.74%0.15%0.82%-0.42%5.03%
EPS (Basic)
0.560.620.400.690.640.60
EPS (Diluted)
0.560.620.400.690.640.60
EPS Growth
43.85%55.00%-42.03%7.81%6.67%-30.30%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
236.82194.19159.14151.96115.92110.33
Free Cash Flow Per Share
1.160.960.790.760.580.55
Dividend Per Share
0.2500.2500.1250.2100.2070.143
Dividend Growth
100.00%100.00%-40.48%1.50%44.99%-39.99%
Gross Margin
39.25%39.13%39.83%43.62%56.97%64.65%
Operating Margin
10.50%10.68%7.70%10.10%9.04%10.96%
Profit Margin
8.62%8.80%5.22%8.54%8.12%8.68%
Free Cash Flow Margin
17.84%13.63%10.35%9.38%7.39%7.99%
EBITDA
215.17228.93205.65241.03202.87197.6
EBITDA Margin
16.21%16.07%13.37%14.87%12.93%14.31%
D&A For EBITDA
75.8476.7487.2877.3961.146.36
EBIT
139.33152.19118.37163.64141.77151.25
EBIT Margin
10.50%10.68%7.70%10.10%9.04%10.96%
Effective Tax Rate
11.46%13.06%4.09%11.65%10.18%18.14%
Revenue as Reported
1,4251,4251,5381,6261,5681,380
Advertising Expenses
-134.93146.29251.93526.87585.69